29.57
-0.72 (-2.36%)
| Penutupan Terdahulu | 30.28 |
| Buka | 29.79 |
| Jumlah Dagangan | 86,902 |
| Purata Dagangan (3B) | 291,386 |
| Modal Pasaran | 1,323,748,992 |
| Harga / Jualan (P/S) | 55.75 |
| Harga / Buku (P/B) | 3.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2026 |
| Margin Operasi (TTM) | -11,831.05% |
| EPS Cair (TTM) | -1.78 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -30.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.25% |
| Nisbah Semasa (MRQ) | 32.19 |
| Aliran Tunai Operasi (OCF TTM) | -74.10 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -25.69 M |
| Pulangan Atas Aset (ROA TTM) | -17.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Septerna, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.40 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 2.64% |
| % Dimiliki oleh Institusi | 105.46% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Trv Gp Vi, Llc | 31 Dec 2025 | 4,211,659 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (Wells Fargo, 62.35%) | Beli |
| Median | 40.00 (35.30%) | |
| Rendah | 34.00 (Truist Securities, 15.00%) | Beli |
| Purata | 40.60 (37.33%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 28.82 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 03 Mar 2026 | 48.00 (62.35%) | Beli | 29.57 |
| HC Wainwright & Co. | 02 Mar 2026 | 40.00 (35.30%) | Beli | 29.57 |
| 20 Jan 2026 | 35.00 (18.38%) | Beli | 27.03 | |
| Jones Trading | 23 Dec 2025 | 43.00 (45.44%) | Beli | 28.23 |
| Raymond James | 19 Dec 2025 | 38.00 (28.53%) | Beli | 29.58 |
| Truist Securities | 15 Dec 2025 | 34.00 (15.00%) | Beli | 27.18 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer |
| 17 Dec 2025 | Pengumuman | Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |